NPPB

CAS No. 107254-86-4

NPPB( —— )

Catalog No. M20908 CAS No. 107254-86-4

NPPB is a chloride channel blocker with IC50 of 80 nM .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 In Stock
10MG 48 In Stock
25MG 89 In Stock
50MG 151 In Stock
100MG 259 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NPPB
  • Note
    Research use only, not for human use.
  • Brief Description
    NPPB is a chloride channel blocker with IC50 of 80 nM .
  • Description
    NPPB is a chloride channel blocker with IC50 of 80 nM .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Chloride Channel
  • Recptor
    Chloride channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    107254-86-4
  • Formula Weight
    300.31
  • Molecular Formula
    C16H16N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:150 mg/mL (499.48 mM)
  • SMILES
    O=C(O)c1cc([N+](=O)[O-])ccc1NCCCc1ccccc1
  • Chemical Name
    5-Nitro-2-(3-phenylpropylamino) benzoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Taniguchi Y Tonai-Kachi H Shinjo K . 5-Nitro-2-(3-Phenylpropylamino)benzoic Acid Is a GPR35 Agonist[J]. Pharmacology 2008 82(4):245-249.
molnova catalog
related products
  • ZINC00881524

    ZINC00881524 is an effective and specific ROCK inhibitor.

  • Afoxolaner

    Afoxolaner is an isoxazoline insecticide/acaricide against Ixodes scapularis in dogs.

  • DCPIB

    DCPIB, a known specific and potent inhibitor of volume-regulated anion channels (VRAC),DCPIB displayed superior selectivity toward TRESK with an IC50 of 0.14 μM, demonstrating at least 100-fold higher affinity over TREK1/TRAAK channels.?DCPIB, a known specific and potent inhibitor of volume-regulated anion channels (VRAC), has been reported to activate TREK1 and TREK2 in astrocytes and in vitro recently.?